<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01926548</url>
  </required_header>
  <id_info>
    <org_study_id>CJ_IMM_101</org_study_id>
    <nct_id>NCT01926548</nct_id>
  </id_info>
  <brief_title>to Evaluate the Pharmacokinetics(Cmax, Auc) of CJ Imatinib Mesylate Tablet 200mg x 1 Compared With Gleevec Film-coated Tablet 100mg x 2 in Healthy Male Volunteers</brief_title>
  <official_title>Open-label, Randomized, Single-dose, 2-way Crossover Study to Evaluate the Pharmacokinetics(Cmax, Auc) of CJ Imatinib Mesylate Tablet 200mg x 1 Compared With Gleevec Film-coated Tablet 100mg x 2 in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CJ HealthCare Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CJ HealthCare Corporation</source>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the pharmacokinetics of CJ Imatinib mesylate tablet 1 x
      200mg compared with Gleevec film-coated tablet 2 x 100mg in healthy male volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>maximum concentration, Area under the concentration-time curve from zero to infinity</measure>
    <time_frame>Blood sampling up to 72hs post dose(16 times).</time_frame>
    <description>Administration of IP : 1day</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to peak concentration, t1/2, Area under the concentration-time curve from zero to infinity</measure>
    <time_frame>Blood sampling up to 72hs post dose(16 times).</time_frame>
    <description>Administration of IP : 1 day</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>CJ Imatinib 200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 tablet(200mg) a day,PO,QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gleevec 100mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 tablet(100mg) a day,PO,QD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CJ Imatinib mesylate tablet</intervention_name>
    <arm_group_label>CJ Imatinib 200mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gleevec film-coated tablet 2 x 100mg</intervention_name>
    <arm_group_label>Gleevec 100mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male volunteers in the age between 20 and 55 years old

          -  Judged to be in good health on the basis of their vital sign, ECG, physical exam and
             routine laboratory data

          -  Body Mass Index (BMI) in the range of 18.5 to 27 kg/m2

          -  Available for the entire study period

          -  Willing to adhere to protocol requirements and sign a informed consent form

        Exclusion Criteria:

          -  History of clinically significant hepatic, renal, neurology, psychiatric, pulmonary,
             endocrine, hematologic, cardiovascular disease

          -  Clinically significant vital sign

               -  SBP(Systolic Blood Pressure) ≤ 90 mmHg or SBP ≥ 140 mmHg

               -  DBP(Diastolic Blood Pressure) ≤ 60 mmHg or DBP ≥ 100 mmHg

          -  History of surgery except or gastrointestinal disease which might significantly change
             absorption of medicines

          -  History of clinically significant allergies, including imatinib

          -  Clinical laboratory test values are outside the accepted normal range

               -  AST(ASpartate Transaminase), ALT(ALanine Transaminase)( &gt; 1.5 times to normal
                  range

               -  Estimated GFR(Glomerular Filtration Rate) &lt; 80 mL/min

          -  History of caffeine, alcohol, smoking abuse

               -  caffeine &gt; 4 cups/day

               -  grapefruit juice &gt; 4 cups/day

               -  smoking &gt; 20 cigarettes/day

               -  alcohol &gt; 140g/week

          -  Participated in a previous clinical trial within 3 months prior to dosing

          -  Donated blood within 60 days prior to dosing

          -  Use of prescription only medicine and oriental medicine within the 14 days before
             dosing or use of non-prescription medicine within the 10 days before dosing

          -  Subjects considered as unsuitable based on medical judgement by investigators
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 14, 2013</study_first_submitted>
  <study_first_submitted_qc>August 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2013</study_first_posted>
  <last_update_submitted>August 20, 2013</last_update_submitted>
  <last_update_submitted_qc>August 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Safety</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

